NanoViricides (NYSE:NNVC) Now Covered by Analysts at StockNews.com

Posted by on Jun 8th, 2023

Equities researchers at StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC – Get Rating) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.

Separately, EF Hutton Acquisition Co. I dropped their price target on shares of NanoViricides from $8.50 to $5.25 and set a “buy” rating for the company in a research note on Tuesday, February 28th.

NanoViricides Trading Down 2.7 %

NYSE NNVC opened at $1.10 on Thursday. The stock has a market cap of $12.80 million, a price-to-earnings ratio of -1.86 and a beta of 1.10. NanoViricides has a 12 month low of $1.04 and a 12 month high of $3.88. The company’s 50 day moving average is $1.23 and its two-hundred day moving average is $1.34.

Hedge Funds Weigh In On NanoViricides

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC increased its position in NanoViricides by 59.1% during the fourth quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock worth $75,000 after buying an additional 25,012 shares during the period. Two Sigma Investments LP acquired a new stake in shares of NanoViricides during the third quarter worth about $59,000. Vanguard Group Inc. grew its holdings in shares of NanoViricides by 7.1% during the third quarter. Vanguard Group Inc. now owns 458,072 shares of the company’s stock worth $792,000 after buying an additional 30,194 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of NanoViricides by 18.4% during the third quarter. Renaissance Technologies LLC now owns 71,066 shares of the company’s stock worth $123,000 after buying an additional 11,066 shares during the last quarter. Finally, UBS Group AG increased its position in NanoViricides by 114.5% in the 1st quarter. UBS Group AG now owns 17,448 shares of the company’s stock valued at $37,000 after acquiring an additional 9,314 shares during the period. Hedge funds and other institutional investors own 11.43% of the company’s stock.

NanoViricides Company Profile

(Get Rating)

NanoViricides, Inc is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R.

Read More

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.